Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218684 | 0.81 | MEN1 (0.58) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL29566671 | 0.81 | MEN1 (0.58) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6219515 | 0.79 | MEN1 (0.56) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6218498 | 0.79 | KMT2A (0.56) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL6139615 | 0.79 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL6139614 | 0.79 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL24309773 | 0.78 | KMT2A (0.55) | MEN1KMT2ALMNAMAPTSMN1; SMN2 | |
| SCHEMBL3026269 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL5747941 | 0.77 | MEN1 (0.53) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL27201517 | 0.75 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844337-B2 | 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, their preparation and their application in therapeutics | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| EP-1289986-B1 | 1,4-DIAZABICYCLO 3.2.2]NONANE-PHENYLISOXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-04-28 | — | — | EP | disclosed |
| US-20030114461-A1 | 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114461-A1 | 1,4-Diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof | CYC1, GLRA1, CBR1 | MEN1 1537/4885KMT2A 3489/4885ALDH1A1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.